Skip to main content
Fig. 4 | Stem Cell Research & Therapy

Fig. 4

From: Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease

Fig. 4

Human bmMSCs, ucMSCs, kPSCs or CM-ucMSCs decrease renal macrophage infiltration. a Quantification of ED1-positive monocytes/macrophages per field in renal tissue of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Data are mean ± SE. ***p < 0.001 vs control; °°p < 0.01 vs ADR + saline. b Quantification of macrophages with anti-inflammatory M2 phenotype expressed as percentage of CD206-positive macrophages per total ED1-positive cells in renal sections of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Data are mean ± SE. ***p < 0.001 vs control; °°°p < 0.001 vs ADR + saline; ###p < 0.001 vs ADR + saline + bmMSCs or kPSCs. c Representative images of ED1-positive monocytes/macrophages (green) and anti-inflammatory M2 macrophages labelled with CD206 (red) in renal tissue of control and ADR rats receiving saline, bmMSCs, ucMSCs, kPSCs or CM-ucMSCs at 14 days. Nuclei stained with DAPI (blue). Scale bar 20 μm. ADR adriamycin, bmMSC bone marrow-derived mesenchymal stromal cell, CM-ucMSC conditioned medium obtained from umbilical cord-derived mesenchymal stromal cell, DAPI 4′,6-diamidino-2-phenylindole, kPSC kidney perivascular stromal cell

Back to article page